Bcr/Abl activates transcription of theBcl-X gene through STAT5
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Several tyrosine kinase oncogenes have been associated with myeloproliferative diseases, including Bcr/Abl, Tel/Abl, Tel/Jak2, and Tel/PDGFR. One target molecule shared by these oncogenes is known to be STAT5. We generated sublines of Ba/F3 cells in which either wild-type STAT5 or a constitutively active mutant of STAT5 (STAT5-1*6) were expressed under the control of a tetracycline-inducible promoter. These cell lines were compared with a Ba/F3 cell line in which the expression of p210Bcr/Abl was made inducible by a similar promoter. Before induction, all cells were dependent on interleukin 3 (IL-3) for growth and survival. Both STAT5-1*6 and Bcr/Abl enhanced viability and induced proliferation in the absence of IL-3. We found that the proviability protein Bcl-XL, but not Bcl-2, was induced by both p210Bcr/Abl and STAT5-1*6. Using a Bcl-X gene promoter construct fused to a luciferase complementary DNA (cDNA), both p210Bcr/Abl and STAT5-1*6 were shown to induce transcription of Bcl-X. The increase in transcription of the Bcl-X promoter and the increase in Bcl-X protein, due to p210Bcr/Abl, were blocked by expression of a dominant negative STAT5 mutant. Interestingly, however, STAT5-1*6 required the continued presence of IL-3 to cause a significant increase in Bcl-XL protein, whereas p210Bcr/Abl did not need IL-3. Studies with enzyme inhibitors suggest that the extra signal supplied by IL-3 may be supplied by the PI3K pathway. Overall, these data suggest that constitutively activated STAT5 can increase viability and proliferation of Ba/F3 cells. This may contribute to, but is not likely sufficient for, the enhanced viability associated with Bcr/Abl transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
STATs: Signal Transducers and Activators of Transcription
Ihle, J. N. (1996) · Cell · doi:10.1016/s0092-8674(00)81277-5 · Cited by 1,381
Teglund, S., McKay, C., Schuetz, E., van Deursen, J. M., Stravopodis, D., Wang, D., Brown, M., Bodner, S., Grosveld, G., & Ihle, J. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81444-0 · Cited by 1,267
Chromosome Studies on Normal and Leukemic Human Leukocytes
(1960) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/25.1.85 · Cited by 1,069
The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid Gene
Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A.-M., Witte, O. N., & Baltimore, D. (1986) · Science · doi:10.1126/science.3460176 · Cited by 806
Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5a−/−5b−/− Mice
Socolovsky, M., Fallon, A. E. J., Wang, S., Brugnara, C., & Lodish, H. F. (1999) · Cell · doi:10.1016/s0092-8674(00)81013-2 · Cited by 696
Skorski, T., Bellacosa, A., Nieborowska‐Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., et al. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6151 · Cited by 567
Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
Matsumoto, A., Masuhara, M., Mitsui, K., Yokouchi, M., Ohtsubo, M., Misawa, H., Miyajima, A., & Yoshimura, A. (1997) · Blood · doi:10.1182/blood.v89.9.3148 · Cited by 528
Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
Bedi, A., Zehnbauer, B., Barber, J., Sharkis, S., & Jones, R. (1994) · Blood · doi:10.1182/blood.v83.8.2038.2038 · Cited by 508
Carlesso, N., Frank, D. A., & Griffin, J. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.811 · Cited by 483
Self-citationBcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Puil, L., Liu, J., Gish, G., Mbamalu, G., Bowtell, D., Pelicci, P. G., Arlinghaus, R., & Pawson, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06319.x · Cited by 438
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., & Sawyers, C. L. (1996) · PubMed · Cited by 434
Onishi, M., Nosaka, T., Misawa, K., Mui, A. L.-F., Gorman, D., McMahon, M., Miyajima, A., & Kitamura, T. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3871 · Cited by 412
Dominant negative MYC blocks transformation by ABL oncogenes
Sawyers, C. L., Callahan, W., & Witte, O. N. (1992) · Cell · doi:10.1016/0092-8674(92)90241-4 · Cited by 397
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Raitano, A. B., Halpern, J. R., Hambuch, T. M., & Sawyers, C. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11746 · Cited by 394
Horita, M., Andreu, E. J., Benito, A., Arbona, C., Sanz, C., Benet, I., Prosper, F., & Fernandez-Luna, J. L. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.977 · Cited by 366
Bedi, A., Barber, J., Bedi, G., el-Deiry, W., Sidransky, D., Vala, M., Akhtar, A., Hilton, J., & Jones, R. (1995) · Blood · doi:10.1182/blood.v86.3.1148.1148 · Cited by 349
Gouilleux-Gruart, V, Gouilleux, F., Desaint, C., Claisse, J., Capiod, J., Delobel, J., Weber-Nordt, R., Dusanter-Fourt, I., Dreyfus, F., Groner, B., et al. (1996) · Blood · doi:10.1182/blood.v87.5.1692.1692 · Cited by 316
Silva, M., Benito, A., Sanz, C., Prosper, F., Ekhterae, D., Nuñez, G., & Fernandez-Luna, J. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22165 · Cited by 277
Nieborowska-Skorska, M., Wasik, M. A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., & Skorski, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1229 · Cited by 271
Moriggl, R., Gouilleux-Gruart, V., Jähne, R., Berchtold, S., Gartmann, C., Liu, X., Hennighausen, L., Sotiropoulos, A., Groner, B., & Gouilleux, F. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5691 · Cited by 265
Yoshimura, A., Ichihara, M., Kinjyo, I., Moriyama, M., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Hara, T., & Miyajima, A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00443.x · Cited by 213
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells
Sillaber, C., Gesbert, F., Frank, D. A., Sattler, M., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v95.6.2118 · Cited by 198
Self-citationTumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.
Sánchez-García, I., & Grütz, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5287 · Cited by 192
Genomic organization, promoter region analysis, and chromosome localization of the mouse bcl-x gene
Grillot, D. A., González-García, M., Ekhterae, D., Duan, L., Inohara, N., Ohta, S., Seldin, M. F., & Nuñez, G. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.10.4750 · Cited by 186
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation
Kieslinger, M., Woldman, I., Moriggl, R., Hofmann, J., Marine, J.-C., Ihle, J. N., Beug, H., & Decker, T. (2000) · Genes & Development · doi:10.1101/gad.14.2.232 · Cited by 185
Neshat, M. S., Raitano, A. B., Wang, H.-G., Reed, J. C., & Sawyers, C. L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1179-1186.2000 · Cited by 185
Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells
Mandanas, R., Leibowitz, D., Gharehbaghi, K., Tauchi, T., Burgess, G., Miyazawa, K., Jayaram, H., & Boswell, H. (1993) · Blood · doi:10.1182/blood.v82.6.1838.1838 · Cited by 165
IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line
Dumon, S., Santos, S. C. R., Debierre-Grockiego, F., Gouilleux-Gruart, V, Cocault, L., Boucheron, C., Mollat, P., Gisselbrecht, S., & Gouilleux, F. (1999) · Oncogene · doi:10.1038/sj.onc.1202796 · Cited by 159
Nakajima, H., Brindle, P. K., Handa, M., & Ihle, J. N. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6836 · Cited by 129
Secondary Mutation Maintains the Transformed State in BaF3 Cells With Inducible BCR/ABL Expression
Klucher, K. M., Lopez, D. V., & Daley, G. Q. (1998) · Blood · doi:10.1182/blood.v91.10.3927 · Cited by 123
Fusion of the ets Transcription Factor TEL to Jak2 Results in Constitutive Jak-Stat Signaling
Ho, J. M.-Y., Beattie, B. K., Squire, J. A., Frank, D. A., & Barber, D. L. (1999) · Blood · doi:10.1182/blood.v93.12.4354 · Cited by 111
Mui, A. L.-F., Wakao, H., Harada, N., O’Farrell, A.-M., & Miyajima, A. (1995) · Journal of Leukocyte Biology · doi:10.1002/jlb.57.5.799 · Cited by 101
Carlesso, N., Griffin, J. D., & Druker, B. J. (1994) · PubMed · Cited by 66
Self-citationBCR/ABL confers growth factor independence upon a murine myeloid cell line.
Mandanas, R., Boswell, H. S., Lu, L., & Leibowitz, D. S. (1992) · PubMed · Cited by 45
Cited by
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
Levis, M., Allebach, J., Tse, K.-F., Zheng, R., Baldwin, B. R., Smith, B. D., Jones-Bolin, S., Ruggeri, B., Dionne, C., & Small, D. (2002) · Blood · doi:10.1182/blood.v99.11.3885 · Cited by 475
Metadata
- Authors
- Gesbert, F., & Griffin, J. D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-09-15
- Volume
- 96
- Issue
- 6
- Pages
- 2269-2276
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2224782492
- Cited by
- 253
- References
- 36
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.